MED17 sirna

MED17 siRNA (Mouse)

Cat. Num. AAA8241251

• Gene Names: Med17; 77kDa; Crsp6; Trap80; C330002H14Rik
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: MED17; MED17 siRNA (Mouse); CRSP6; TRAP80; Mediator of RNA polymerase II transcription subunit 17; Cofactor required for Sp1 transcriptional activation subunit 6; CRSP complex subunit 6; Mediator complex subunit 17; Thyroid hormone receptor-associated protein complex 80 kDa component; MED17 sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: MED17 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 649

• Applicable Applications for MED17 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse MED17 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for MED17 sirna

siRNA to inhibit MED17 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 21450345
• NCBI GeneID: 234959
• NCBI Accession #: NP_659182.1
• NCBI GenBank Nucleotide #: NM_144933.1
• UniProt Accession #: Q8VCD5; Q8BYS6; Q99KQ1
• Molecular Weight: 72,462 Da
• NCBI Official Full Name: mediator of RNA polymerase II transcription subunit 17
• NCBI Official Synonym Full Names: mediator complex subunit 17
• NCBI Official Symbol: Med17
• NCBI Official Synonym Symbols: 77kDa; Crsp6; Trap80; C330002H14Rik
• NCBI Protein Information: mediator of RNA polymerase II transcription subunit 17
• UniProt Protein Name: Mediator of RNA polymerase II transcription subunit 17
• Protein Family: Mediator of RNA polymerase II transcription
• UniProt Gene Name: Med17
• UniProt Synonym Gene Names: Crsp6; Trap80; CRSP complex subunit 6
• UniProt Entry Name: MED17_MOUSE

Uniprot Description

MED17: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Defects in MED17 are the cause of microcephaly postnatal progressive with seizures and brain atrophy (MCPHSBA). It is a disorder characterized by postnatal progressive microcephaly and severe developmental retardation associated with cerebral and cerebellar atrophy. Infants manifest swallowing difficulties leading to failure to thrive, jitteriness, poor visual fixation, truncal arching, seizures. There is no acquisition of developmental milestones and patients suffer from marked spasticity and profound retardation. Progressive microcephaly becomes evident few months after birth. Belongs to the Mediator complex subunit 17 family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Nuclear receptor co-regulator; Transcription, coactivator/corepressor

Cellular Component: transcription factor complex; membrane; Srb-mediator complex; nucleus; ubiquitin ligase complex

Molecular Function: transcription coactivator activity; transcription cofactor activity; thyroid hormone receptor binding; receptor activity

Biological Process: regulation of transcription from RNA polymerase II promoter; steroid hormone receptor signaling pathway; transcription initiation from RNA polymerase II promoter; regulation of transcription, DNA-dependent; transcription, DNA-dependent; positive regulation of transcription, DNA-dependent; androgen receptor signaling pathway; stem cell maintenance; protein ubiquitination; positive regulation of transcription from RNA polymerase II promoter